Safety and immunogenicity of an MF59™-adjuvanted subunit influenza vaccine in elderly Chinese subjects

Immunity and Ageing

Volumn 5, Issue , 2008, Pages

  Li, Rongcheng ^a   Fang, Hanhua ^b   Li, Yanping ^a   Liu, Youping ^c   Pellegrini, Michele ^d   Podda, Audino ^d  

^a Guangxi Zhuang Autonomous Region Environmental Monitoring Station   (China)

^b NATIONAL INSTITUTE FOR THE CONTROL OF PHARMACEUTICAL AND BIOLOGICAL PRODUCTS   (China)

^c Center for Disease Prevention and Control of Wuzhou   (China)

^d NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE ADJUVANTED SUBUNIT INFLUENZA VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; CHINESE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG SAFETY; DRUG TOLERABILITY; ECZEMA; FATIGUE; FEVER; HEADACHE; HUMAN; IMMUNOGENICITY; INFLUENZA; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE RASH; INJECTION SITE SWELLING; IRRITABILITY; MAJOR CLINICAL STUDY; MYALGIA; NOSE DISEASE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SIDE EFFECT; SKIN DISEASE; STRAIN DIFFERENCE; UNSPECIFIED SIDE EFFECT; VACCINATION; VIRUS STRAIN; VOMITING;

EID: 42049089782     PISSN: 17424933     EISSN: None     Source Type: Journal    
DOI: 10.1186/1742-4933-5-2     Document Type: Article

References (35)

1. World Health Organization WHO factsheet 211: Influenza 2003 http://who.int/mediacentre/factsheets/2003/fs211/en/print.html Accessed February 2007
2. World Health Organization Influenza vaccines: WHO position paper Wkly Epidemiol Rec 2005, 80:279-287 16171031
3. Webster RG Predictions for future human influenza pandemics J Infect Dis 1997, 176:S14-19 10.1086/514168 9240688
4. Huang P Ni H Shen G Zhou H Peng G Liu S Analysis of the 1991-2000 influenza epidemic in Guangdong Province, China Southeast Asian J Trop Med Public Health 2001, 32:787-790 12041555
5. Nicholson KG Wood JM Zambon M Influenza Lancet 2003, 362:1733-1745 10.1016/S0140-6736(03)14854-4 14643124
6. Shortridge KF Severe acute respiratory syndrome and influenza: Virus incursions from southern China Am J Respir Crit Care Med 2003, 168:1416-1420 10.1164/rccm.2310005 14668255
7. Viboud C Alonso WJ Simonsen L Influenza in tropical regions PLoS Med 2006, 3:e89 1391975 16509764 10.1371/journal.pmed.0030089
8. He J Gu D Wu X Reynolds K Duan X Yao C Wang J Chen C-S Chen J Wildman RP Klag MJ Whelton PK Major causes of death among men and women in China N Engl J Med 2005, 353:1124-1134 10.1056/NEJMsa050467 16162883
9. Targonski PV Jacobson RM Poland GA Immunosenescence: Role and measurement in influenza vaccine response among the elderly Vaccine 2007, 25:3066-3069 10.1016/j.vaccine.2007.01.025 17275144
10. Wong CM Chan KP Hedley AJ Peiris JS Influenza-associated mortality in Hong Kong Clin Infect Dis 2004, 39:1611-1617 10.1086/425315 15578360
11. Hsieh YC Chen HY Yen JJ Liu PD Chang LY Lu CY Shao PL Lee CY Huang LM Influenza in Taiwan: Seasonality and vaccine strain match J Microbiol Immunol Infect 2005, 38:238-243 16118670
12. Wong CM Yang L Chan KP Leung G Chan KH Guan Y Lam TH Hedley AJ Peiris JSM Influenza-associated hospitalization in a subtropical city PLoS Med 2006, 3:e121 1391978 16515368 10.1371/journal.pmed.0030121
13. Nichol KL The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines Vaccine 2003, 21:1769-1775 10.1016/ S0264-410X(03)00070-7 12686092
14. Centers for Disease Control and Prevention (CDC) Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2007 MMWR Recomm Rep 2007, 56:1-54
15. Goodwin K Viboud C Simonsen L Antibody response to influenza vaccination in the elderly: A quantitative review Vaccine 2006, 24:1159-1169 10.1016/ j.vaccine.2005.08.105 16213065
16. Gardner EM Gonzalez EW Nogusa S Murasko DM Age-related changes in the immune response to influenza vaccination in a racially diverse, healthy elderly population Vaccine 2006, 24:1609-1614 10.1016/ j.vaccine.2005.09.058 16260072
17. Hsu LC Lin SR Hsu HM Chao WH Hsieh JT Wang MC Lu CF Chang YH Ho MS Ethnic differences in immune responses to hepatitis B vaccine Am J Epidemiol 1996, 143:718-724 8651234
18. Jianping H Xin F Changshun L Bo Z Linxiu G Wei X Jiande S Assessment of effectiveness of Vaxigrip Vaccine 1999, 17(Suppl 1):S57-58 10.1016/ S0264-410X(99)00107-3 10471182
19. Hui SL Chu LW Peiris JSM Chan KH Chu D Tsui W Immune response to influenza vaccination in community-dwelling Chinese elderly persons Vaccine 2006, 24:5371-5380 10.1016/j.vaccine.2006.04.032 16713661
20. Wang C-S Wang S-T Lai C-T Lin L-J Chou P Impact of influenza vaccination on major cause-specific mortality Vaccine 2007, 25:1196-1203 10.1016/ j.vaccine.2006.10.015 17097773
21. Li Q Wang L-J Wu H-Y Song T Rapid investigation of influenza-like cases incidence in Beijing urban area (2001) Chinese J Vaccines Immunization 2003, 5:277-279
22. Kincannon CL He W West LA Demography of aging in China and the United States and the economic well-being of their older populations J Cross Cult Gerontol 2005, 20:243-255 10.1007/s10823-006-9015-1 17041789
23. Podda A Del Giudice G O'Hagan DT MF59™: A safe and potent adjuvant for human use Immunopotentiators in modern vaccines Amsterdam: Academic Press Schijns VEJC, O'Hagan DT 2006 149-159
24. Baldo V Menegon T Bonello C Floreani A Trivello R Mariutto Collaborative Group Comparison of three different influenza vaccines in institutionalised elderly Vaccine 2001, 19:3472-3475 10.1016/ S0264-410X(01)00060-3 11348713
25. Podda A The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine Vaccine 2001, 19:2673-2680 10.1016/S0264-410X(00)00499-0 11257408
26. Iob A Brianti G Zamparo E Gallo T Evidence of increased clinical protection of an MF59-adjuvant influenza vaccine compared to a non-adjuvant vaccine among elderly residents of long-term care facilities in Italy Epidemiol Infect 2005, 133:687-693 10.1017/ S0950268805003936 16050515
27. Banzhoff A Nacci P Podda A A new MF59™-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: Results from an immunogenicity meta-analysis Gerontology 2003, 49:177-184 10.1159/000069172 12679609
28. De Donato S Granoff D Minutello M Lecchi G Faccini M Agnello M Senatore F Verweij P Fritzell B Podda A Safety and immunogenicity of MF59™-adjuvanted influenza vaccine in the elderly Vaccine 1999, 17:3094-3101 10.1016/S0264-410X(99)00138-3 10462245
29. Del Giudice G Hilbert AK Bugarini R Minutello A Popova O Toneatto D Schoendorf I Borkowski A Rappuoli R Podda A An MF59™-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine Vaccine 2006, 24:3063-3065 10.1016/j.vaccine.2006.01.015 16464520
30. Puig-Barberà J Diez-Domingo J Hoyos SP Varea AB Vidal DG Effectiveness of the MF59™-adjuvanted influenza vaccine in preventing emergency admissions for pneumonia in the elderly over 64 years of age Vaccine 2004, 23:283-289 10.1016/j.vaccine.2004.07.017 15530669
31. Puig-Barberà J Díez-Domingo J Varea AB Chavarri GS Rodrigo JAL Pérez-Hoyos S Vidal DG Effectiveness of MF59™-adjuvanted subunit influenza vaccine in preventing hospitalisations for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly Vaccine 2007, 25:7313-7321 10.1016/ j.vaccine.2007.08.039 17889411
32. O'Hagan DT MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection Expert Rev Vaccines 2007, 6:699-710 10.1586/14760584.6.5.699 17931151
33. D'Agosto V Berardi S Burroni D Hennig R Tolerability and safety of an MF59-adjuvanted subunit influenza vaccine (FLUAD®) Poster presented at the 2nd International Conference on Influenza Vaccines for the World (IVW), Vienna, Austria 18-20 October 2006
34. Committee for Proprietary Medicinal Products (CPMP) Note for guidance on harmonisation of requirements for influenza vaccines. CPMP/BWP/214/96. 12 March 1997 http://www.emea.europa.eu/pdfs/human/bwp/021496en.pdf accessed November 2007
35. Potter CW Oxford JS Determinants of immunity to influenza infection in man Br Med Bull 1979, 35:69-75 367490